Cargando…

Pan-Bcl-2 Inhibitor AT-101 Enhances Tumor Cell Killing by EGFR Targeted T Cells

Pancreatic cancer is a deadly disease and has the worst prognosis among almost all cancers and is in dire need of new and improved therapeutic strategies. Conditioning of tumor cells with chemotherapeutic drug has been shown to enhance the anti-tumor effects of cancer vaccines and adoptive cell ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thakur, Archana, Lum, Lawrence G., Schalk, Dana, Azmi, Asfar, Banerjee, Sanjeev, Sarkar, Fazlul H., Mohommad, Ramzi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3501501/ https://www.ncbi.nlm.nih.gov/pubmed/23185240 http://dx.doi.org/10.1371/journal.pone.0047520

Ejemplares similares

Microenvironment generated during EGFR targeted killing of pancreatic tumor cells by ATC inhibits myeloid-derived suppressor cells through COX2 and PGE(2) dependent pathway
por: Thakur, Archana, et al.
Publicado: (2013)

Small Molecule Inhibitors of Bcl-2 Family Proteins for Pancreatic Cancer Therapy
por: Masood, Ashiq, et al.
Publicado: (2011)

Progress in Nanotechnology Based Approaches to Enhance the Potential of Chemopreventive Agents
por: Muqbil, Irfana, et al.
Publicado: (2011)

Hypoxia Induced Aggressiveness of Prostate Cancer Cells Is Linked with Deregulated Expression of VEGF, IL-6 and miRNAs That Are Attenuated by CDF
por: Bao, Bin, et al.
Publicado: (2012)

MI-219-Zinc Combination: a new Paradigm in MDM2 Inhibitor Based Therapy
por: Azmi, Asfar S., et al.
Publicado: (2010)

Pro-oxidant activity of dietary chemopreventive agents: an under-appreciated anti-cancer property
por: Azmi, Asfar S, et al.
Publicado: (2013)

Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients
por: Lum, Lawrence G., et al.
Publicado: (2020)

Hypoxia-Induced Aggressiveness of Pancreatic Cancer Cells Is Due to Increased Expression of VEGF, IL-6 and miR-21, Which Can Be Attenuated by CDF Treatment
por: Bao, Bin, et al.
Publicado: (2012)

Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies
por: Zitron, Ian M, et al.
Publicado: (2013)

SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status
por: Al-Katib, Ayad M, et al.
Publicado: (2009)

Five advanced pancreatic cancer patients in a Phase I study of anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (BATS)
por: Lum, Lawrence G, et al.
Publicado: (2015)

Network Modeling of MDM2 Inhibitor-Oxaliplatin Combination Reveals Biological Synergy in wt-p53 solid tumors
por: Azmi, Asfar S., et al.
Publicado: (2011)

Activated K-ras and INK4a/Arf Deficiency Cooperate During the Development of Pancreatic Cancer by Activation of Notch and NF-κB Signaling Pathways
por: Wang, Zhiwei, et al.
Publicado: (2011)

Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells
por: Thakur, Archana, et al.
Publicado: (2021)

Priming of pancreatic cancer cells with bispecific antibody armed activated T cells sensitizes tumors for enhanced chemoresponsiveness
por: Thakur, Archana, et al.
Publicado: (2021)

Vaccination with bispecific antibody armed T cells (BATC) in metastatic breast cancer patients and transfer of anti-breast cancer immunity in primed T cells after stem cell transplant: a proof of principle study
por: Thakur, Archana, et al.
Publicado: (2015)

Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-X(L )and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model
por: Arnold, Alan A, et al.
Publicado: (2008)

Anti-CS1 × Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1(+) Myeloma Cells and Release Type-1 Cytokines
por: Lum, Lawrence G., et al.
Publicado: (2020)

Systems analysis reveals a transcriptional reversal of the mesenchymal phenotype induced by SNAIL-inhibitor GN-25
por: Azmi, Asfar S, et al.
Publicado: (2013)

Nuclear Export Inhibition for Pancreatic Cancer Therapy
por: Muqbil, Irfana, et al.
Publicado: (2018)

Epithelial to Mesenchymal Transition Is Mechanistically Linked with Stem Cell Signatures in Prostate Cancer Cells
por: Kong, Dejuan, et al.
Publicado: (2010)

Histone Deacetylase Inhibitors Induce Epithelial-to-Mesenchymal Transition in Prostate Cancer Cells
por: Kong, Dejuan, et al.
Publicado: (2012)

Network insights on oxaliplatin anti-cancer mechanisms
por: Alian, Osama M, et al.
Publicado: (2012)

An antiapoptotic Bcl-2 family protein index predicts the response of leukaemic cells to the pan-Bcl-2 inhibitor S1
por: Zhang, Z, et al.
Publicado: (2013)

CUDC-101 is a potential target inhibitor for the EGFR-overexpression bladder cancer cells
por: Wang, Zhenxing, et al.
Publicado: (2023)

Sensitization of ovarian cancer cells to cisplatin by genistein: the role of NF-kappaB
por: Solomon, Leigh A, et al.
Publicado: (2008)

In Situ immunization by bispecific antibody targeted T cell therapy in breast cancer
por: Thakur, Archana, et al.
Publicado: (2015)

Prime, shock and kill: BCL-2 inhibition for HIV cure
por: Chandrasekar, Aswath P., et al.
Publicado: (2022)

Activation of AMP-Activated Protein Kinase by 3,3′-Diindolylmethane (DIM) Is Associated with Human Prostate Cancer Cell Death In Vitro and In Vivo
por: Chen, Di, et al.
Publicado: (2012)

Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer
por: Ren, Tao, et al.
Publicado: (2015)

BIM mediates synergistic killing of B-cell acute lymphoblastic leukemia cells by BCL-2 and MEK inhibitors
por: Korfi, K, et al.
Publicado: (2016)

Preferential expression of functional IL-17R in glioma stem cells: potential role in self-renewal
por: Parajuli, Prahlad, et al.
Publicado: (2016)

The pan-Bcl-2 inhibitor obatoclax promotes differentiation and apoptosis of acute myeloid leukemia cells
por: Opydo-Chanek, Małgorzata, et al.
Publicado: (2020)

AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations
por: Zhao, Ren, et al.
Publicado: (2016)

ABT-737, a Bcl-2 Selective Inhibitor, and Chloroquine Synergistically Kill Renal Cancer Cells
por: Yin, Pei, et al.
Publicado: (2016)

TCTAP C-101 Lost and Found
por: Yong, David, et al.
Publicado: (2022)

The Complexities of Epidemiology and Prevention of Gastrointestinal Cancers
por: Haq, Saba, et al.
Publicado: (2012)

Pan-Bcl-2 Inhibitor Obatoclax Delays Cell Cycle Progression and Blocks Migration of Colorectal Cancer Cells
por: Koehler, Bruno Christian, et al.
Publicado: (2014)

Killing Two Cells with One Stone: Pharmacologic BCL-2 Family Targeting for Cancer Cell Death and Immune Modulation
por: Ludwig, Lindsey M., et al.
Publicado: (2016)

TACH101, a first-in-class pan-inhibitor of KDM4 histone demethylase
por: Chandhasin, Chandtip, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_koe7c9rgqn8vd7qe8fihtdllua